Michel Moise Habib

Eximore Ltd. develops an ophthalmic medical device. The company was founded by Ishay Attar and Izhar Halahmi in 2014 and is headquartered in Jerusalem, Israel.

Alive israel Healthtech Fund (Alive) is a venture capital firm founded in 2020 by Rafael Beyar, Michel Habib, Ari Shamiss and Dudi Klein. The firm is headquartered in Tel Aviv, Israel.

Omnix Medical Ltd. develops novel antibiotic agents against resistant pathogenic bacterial strains. The company was founded by Moshik Cohen-Kutner, Rekad Kheredin, Niv Bachnoff, and Rom Lakritz in 2015 and is headquartered in Jerusalem, Israel.

Omnix Medical Ltd. develops novel antibiotic agents against resistant pathogenic bacterial strains. The company was founded by Moshik Cohen-Kutner, Rekad Kheredin, Niv Bachnoff, and Rom Lakritz in 2015 and is headquartered in Jerusalem, Israel.

Alive israel Healthtech Fund (Alive) is a venture capital firm founded in 2020 by Rafael Beyar, Michel Habib, Ari Shamiss and Dudi Klein. The firm is headquartered in Tel Aviv, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

BioProtect Ltd. designs, develops and commercializes balloon systems. Its patented technology allows for the design and manufacture of implantable biodegradable balloon products that support a wide range of clinical applications in oncology and surgery. The company’s balloon implant, indicated for prostate cancer patients. BioProtect was founded by Shaul Shohat, Adrian Paz and Abraham Domb in 2004 and is headquartered in Kfar Saba, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Omnix Medical Ltd. develops novel antibiotic agents against resistant pathogenic bacterial strains. The company was founded by Moshik Cohen-Kutner, Rekad Kheredin, Niv Bachnoff, and Rom Lakritz in 2015 and is headquartered in Jerusalem, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Omnix Medical Ltd. develops novel antibiotic agents against resistant pathogenic bacterial strains. The company was founded by Moshik Cohen-Kutner, Rekad Kheredin, Niv Bachnoff, and Rom Lakritz in 2015 and is headquartered in Jerusalem, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

BioProtect Ltd. designs, develops and commercializes balloon systems. Its patented technology allows for the design and manufacture of implantable biodegradable balloon products that support a wide range of clinical applications in oncology and surgery. The company’s balloon implant, indicated for prostate cancer patients. BioProtect was founded by Shaul Shohat, Adrian Paz and Abraham Domb in 2004 and is headquartered in Kfar Saba, Israel.

BioProtect Ltd. designs, develops and commercializes balloon systems. Its patented technology allows for the design and manufacture of implantable biodegradable balloon products that support a wide range of clinical applications in oncology and surgery. The company’s balloon implant, indicated for prostate cancer patients. BioProtect was founded by Shaul Shohat, Adrian Paz and Abraham Domb in 2004 and is headquartered in Kfar Saba, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

BioProtect Ltd. designs, develops and commercializes balloon systems. Its patented technology allows for the design and manufacture of implantable biodegradable balloon products that support a wide range of clinical applications in oncology and surgery. The company’s balloon implant, indicated for prostate cancer patients. BioProtect was founded by Shaul Shohat, Adrian Paz and Abraham Domb in 2004 and is headquartered in Kfar Saba, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Ornim Medical Ltd. provides medical devices and monitering tools. The company is headquartered in Kfar Saba, Israel.

BioProtect Ltd. designs, develops and commercializes balloon systems. Its patented technology allows for the design and manufacture of implantable biodegradable balloon products that support a wide range of clinical applications in oncology and surgery. The company’s balloon implant, indicated for prostate cancer patients. BioProtect was founded by Shaul Shohat, Adrian Paz and Abraham Domb in 2004 and is headquartered in Kfar Saba, Israel.

BioProtect Ltd. designs, develops and commercializes balloon systems. Its patented technology allows for the design and manufacture of implantable biodegradable balloon products that support a wide range of clinical applications in oncology and surgery. The company’s balloon implant, indicated for prostate cancer patients. BioProtect was founded by Shaul Shohat, Adrian Paz and Abraham Domb in 2004 and is headquartered in Kfar Saba, Israel.

BioProtect Ltd. designs, develops and commercializes balloon systems. Its patented technology allows for the design and manufacture of implantable biodegradable balloon products that support a wide range of clinical applications in oncology and surgery. The company’s balloon implant, indicated for prostate cancer patients. BioProtect was founded by Shaul Shohat, Adrian Paz and Abraham Domb in 2004 and is headquartered in Kfar Saba, Israel.

KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel.

Alive israel Healthtech Fund (Alive) is a venture capital firm founded in 2020 by Rafael Beyar, Michel Habib, Ari Shamiss and Dudi Klein. The firm is headquartered in Tel Aviv, Israel.